| Aug 1 |
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
|
| Jul 17 |
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
|
| Jun 26 |
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
|
| Jun 18 |
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
|
| Jun 6 |
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
|
| Jun 5 |
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
|
| Jun 5 |
Vir gains on early mid-stage data for hepatitis candidate
|
| Jun 5 |
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
|
| May 29 |
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 29 |
Vir Biotechnology names Mark Eisner as chief medical officer
|
